Comparing The Effects Of Intermittent And Continuous Endocrine Therapy On Advanced Prostate Cancer

Objective:Compare the pros and cons of intermittent endocrine therapy and continuous endocrine therapy for patients with advanced prostate cancer.Method:A retrospective collection of patients with advanced prostate cancer diagnosed by clinical pathology in Shanxi Bethune Hospital from January 2012 to December 2018,including general information on age,initial PSA,TNM staging,and Gleason score,and strictly followed the inclusion and exclusion criteria.There were 70 patients in total.All patients received the maximum androgen blockade(MAB)treatment plan.According to whether the serum PSA lasted for half a year and was less than or equal to 0.2ng/ml,they were divided into 2 groups.Among them,they received intermittent androgen blockade(IAD).There were 32 patients in the treatment group and 38 patients in the treatment group receiving continuous androgen blockade(CAD).Through regular review and follow-up,the serum PSA changes,adverse reactions,disease progression,and OS survival curves of the two groups of patients were recorded.The above data were analyzed by SPSS25.0software,independent sample t-test was used for the comparison of quantitative data,andχ~2test was used for the comparison of qualitative data.P<0.05 indicates that there is statistical difference.Results:1.There was no statistically significant difference in general data such as age,initial PSA,TNM stage,and Gleason score between the IAD treatment group and the CAD treatment group(P>0.05).2.In the comparison of adverse reactions between IAD treatment group and CAD treatment group,there was significant difference in the overall incidence of adverse reactions between the two groups(P<0.001).There was no significant difference in the incidence of bone pain between the two groups(P>0.05).There were significant differences in the incidence of hot flashes,headache,breast tenderness,sweating and weight gain between the two groups(P<0.05).3.One year after treatment,the patients in the two groups were evaluated with prostate cancer specific quality of life scale EORTC QLQ-PR25.In terms of side effects of drug treatment in patients with advanced prostate cancer,the average score of patients in IAD group was lower than that in CAD group,and there was significant difference between the two groups(P<0.05).The average score of sexual function recovery in IAD group was higher than that in CAD group,and there was significant difference between the two groups(P<0.05).The average score of gastrointestinal symptoms in IAD group was lower than that in CAD group,and there was significant difference between IAD group and CAD group(P<0.05).In terms of urinary tract symptoms,the average score of patients in IAD group was lower than that in CAD group,and there was no significant difference between the two groups(P>0.05).In bone pain symptoms,the average score of IAD group was lower than that of CAD group,and there was no significant difference between the two groups(P>0.05).4.The median time for patients in the IAD treatment group to progress to CRPC was27.00(24.75,30.00)months,and the median time for patients in the CAD treatment group to progress to CRPC was 18.00(18.00,21.00)months.There was significant difference between the two groups(P<0.05).5.In the comparison of OS survival curve between IAD treatment group and CAD treatment group,the overall survival rate of IAD treatment group was better than that of CAD treatment group,and there was no significant difference between the two groups(P>0.05).Conclusion:1.Compared with continuous endocrine therapy,intermittent endocrine therapy can prolong the time for patients to enter CRPC.2.There was no statistical difference in overall survival time between intermittent endocrine therapy and continuous endocrine therapy.3.Compared with continuous endocrine therapy,intermittent endocrine therapy can save treatment costs,reduce the adverse reactions of patients,and improve the quality of life of patients.